Raymond Debbane Purchases 100,000 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Raymond Debbane acquired 100,000 shares of the business’s stock in a transaction on Friday, February 20th. The shares were purchased at an average price of $1.48 per share, for a total transaction of $148,000.00. Following the transaction, the director directly owned 1,804,186 shares of the company’s stock, valued at approximately $2,670,195.28. The trade was a 5.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Raymond Debbane also recently made the following trade(s):

• On Thursday, February 19th, Raymond Debbane bought 50,000 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average price of $1.44 per share, with a total value of $72,000.00.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $1.49 on Wednesday. The stock has a market cap of $539.75 million, a PE ratio of -7.82 and a beta of 0.98. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $1.83. The company has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.31. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47.

Trending Headlines about Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Director Raymond Debbane added to his position with a 100,000-share purchase (~$148k at ~$1.48) on Feb. 20, increasing his stake to ~1.8M shares — a clear insider-confidence signal that can support the share price. Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Raymond Debbane Acquires 100,000 Shares
• Positive Sentiment: Debbane also purchased 50,000 shares (~$72k at ~$1.44) on Feb. 19; the pair of buys total roughly $220k and represent a meaningful insider accumulation for a microcap biotech, which investors often view as a bullish indicator. Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Raymond Debbane Buys 50,000 Shares of Stock
• Positive Sentiment: News coverage tied the insider buying to an intraday price spike (the AIII write-up highlights why LXRX jumped previously), reinforcing that market reaction has been driven by visible insider activity and renewed investor attention. Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 7.18%
• Neutral Sentiment: Company pipeline commentary — reports on shifting trial focus and target refinement — provides longer-term context but no immediate catalyst; these updates are watch-worthy for future data-readout risk/reward. How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials
• Negative Sentiment: Analyst coverage is mixed (several holds and at least one sell rating cited), and consensus remains cautious — that, combined with a low current share price vs. historical targets and notable institutional turnover, can cap upside and help explain downward pressure. MarketBeat LXRX coverage

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LXRX. Wall Street Zen cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $3.23.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Lexicon Pharmaceuticals by 77.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 28,594 shares during the period. Catalyst Funds Management Pty Ltd bought a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at about $51,000. R Squared Ltd purchased a new stake in Lexicon Pharmaceuticals in the second quarter worth about $28,000. Bank of America Corp DE lifted its stake in Lexicon Pharmaceuticals by 27.4% in the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 29,319 shares during the period. Finally, XTX Topco Ltd grew its holdings in Lexicon Pharmaceuticals by 431.4% during the 2nd quarter. XTX Topco Ltd now owns 66,276 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 53,805 shares in the last quarter. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.